These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16460689)

  • 1. Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists.
    Negus SS
    Biochem Pharmacol; 2006 Jun; 71(12):1663-70. PubMed ID: 16460689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inverse agonism: more than reverting constitutively active receptor signaling.
    Dupré DJ; Rola-Pleszczynski M; Stanková J
    Biochem Cell Biol; 2004 Dec; 82(6):676-80. PubMed ID: 15674435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design of receptor partial agonists and possible mechanisms of receptor partial activation: a theory.
    Zhu BT
    J Theor Biol; 1996 Aug; 181(3):273-91. PubMed ID: 8869127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential.
    Daeffler L; Landry Y
    Fundam Clin Pharmacol; 2000; 14(2):73-87. PubMed ID: 10796054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.
    Schneider EH; Strasser A; Thurmond RL; Seifert R
    J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands.
    Miller TR; Baranowski JL; Estvander BR; Witte DG; Carr TL; Manelli AM; Krueger KM; Cowart MD; Brioni JD; Esbenshade TA
    Assay Drug Dev Technol; 2008 Jun; 6(3):339-49. PubMed ID: 18593375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
    Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
    Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonism and inverse agonism at dopamine D2-like receptors.
    Strange PG
    Clin Exp Pharmacol Physiol Suppl; 1999 Apr; 26():S3-9. PubMed ID: 10386247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
    Kenakin T
    ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.
    Berg KA; Clarke WP
    Int J Neuropsychopharmacol; 2018 Oct; 21(10):962-977. PubMed ID: 30085126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse, protean, and ligand-selective agonism: matters of receptor conformation.
    Kenakin T
    FASEB J; 2001 Mar; 15(3):598-611. PubMed ID: 11259378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities.
    Sanders J; Miguel RN; Furmaniak J; Smith BR
    Methods Enzymol; 2010; 485():393-420. PubMed ID: 21050929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists.
    Spadoni G; Balsamini C; Bedini A; Diamantini G; Di Giacomo B; Tontini A; Tarzia G; Mor M; Plazzi PV; Rivara S; Nonno R; Pannacci M; Lucini V; Fraschini F; Stankov BM
    J Med Chem; 1998 Sep; 41(19):3624-34. PubMed ID: 9733487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inverse agonism at serotonin and cannabinoid receptors.
    Aloyo VJ; Berg KA; Clarke WP; Spampinato U; Harvey JA
    Prog Mol Biol Transl Sci; 2010; 91():1-40. PubMed ID: 20691957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study.
    Kooistra AJ; Leurs R; de Esch IJ; de Graaf C
    J Chem Inf Model; 2015 May; 55(5):1045-61. PubMed ID: 25848966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial agonism: mechanisms based on ligand-receptor interactions and on stimulus-response coupling.
    Pliska V
    J Recept Signal Transduct Res; 1999; 19(1-4):597-629. PubMed ID: 10071788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
    de Boer SF; Koolhaas JM
    Eur J Pharmacol; 2005 Dec; 526(1-3):125-39. PubMed ID: 16310183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs.
    Wurch T; Boutet-Robinet EA; Palmier C; Colpaert FC; Pauwels PJ
    J Pharmacol Exp Ther; 2003 Jan; 304(1):380-90. PubMed ID: 12490615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in agonist-independent and -dependent 5-hydroxytryptamine2C receptor-mediated cell division.
    Westphal RS; Sanders-Bush E
    Mol Pharmacol; 1996 Mar; 49(3):474-80. PubMed ID: 8643087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists.
    Wieland K; Bongers G; Yamamoto Y; Hashimoto T; Yamatodani A; Menge WM; Timmerman H; Lovenberg TW; Leurs R
    J Pharmacol Exp Ther; 2001 Dec; 299(3):908-14. PubMed ID: 11714875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.